About Innoviva (NASDAQ:INVA)
Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
Industry, Sector and Symbol
Trailing P/E Ratio14.5982142857143
Forward P/E Ratio8.26
Sales & Book Value
Annual Sales$217.22 million
Price / Sales8.13
Cash Flow$0.69 per share
Price / Cash23.84
Book Value($2.25) per share
Price / Book-7.27
Net Income$134.14 million
Return on Equity-48.93%
Return on Assets35.25%
Innoviva (NASDAQ:INVA) Frequently Asked Questions
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
How were Innoviva's earnings last quarter?
Innoviva Inc (NASDAQ:INVA) announced its earnings results on Thursday, February, 8th. The biotechnology company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.49 by $0.01. The biotechnology company earned $69.52 million during the quarter, compared to analysts' expectations of $67.41 million. Innoviva had a net margin of 61.76% and a negative return on equity of 48.93%. The business's revenue for the quarter was up 59.4% on a year-over-year basis. During the same period last year, the company posted $0.22 earnings per share. View Innoviva's Earnings History.
When will Innoviva make its next earnings announcement?
Where is Innoviva's stock going? Where will Innoviva's stock price be in 2018?
5 brokerages have issued twelve-month target prices for Innoviva's stock. Their predictions range from $8.00 to $17.00. On average, they expect Innoviva's share price to reach $13.40 in the next year. View Analyst Ratings for Innoviva.
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include BTG (BTG), Amicus Therapeutics (FOLD), Emergent Biosolutions (EBS), Hikma Pharmaceuticals (HIK), Horizon Pharma (HZNP), Opko Health (OPK), Corcept Therapeutics (CORT), Cambrex (CBM), Theravance Biopharma (TBPH), Akcea Therapeutics (AKCA), Impax Laboratories (IPXL), Pacira Pharmaceuticals (PCRX), CoLucid Pharmaceuticals (CLCD), Amphastar Pharmaceuticals (AMPH), Collegium Pharmaceutical (COLL), AMAG Pharmaceuticals (AMAG), Lannett (LCI) and SciClone Pharmaceuticals (SCLN).
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- William H. Waltrip, Independent Chairman of the Board (Age 78)
- Eric D'Esparbes, Interim Principal Executive Officer, Chief Financial Officer, Senior Vice President (Age 49)
- Theodore J. Witek Jr., Senior Vice President, Chief Scientific Officer (Age 59)
- George W. Bickerstaff III, Independent Director (Age 62)
- Barbara G. Duncan, Independent Director
- Catherine J. Friedman, Independent Director (Age 56)
- Odysseas D. Kostas M.D., Independent Director (Age 43)
- Patrick G. LePore, Independent Director (Age 62)
Who owns Innoviva stock?
Innoviva's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.45%), Renaissance Technologies LLC (1.41%), Goldman Sachs Group Inc. (0.87%), Geode Capital Management LLC (0.73%), Deutsche Bank AG (0.58%) and Victory Capital Management Inc. (0.55%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, James L Tyree, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.
Who sold Innoviva stock? Who is selling Innoviva stock?
Innoviva's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Deutsche Bank AG, BlackRock Inc., TIAA CREF Investment Management LLC, Two Sigma Investments LP, Goldman Sachs Group Inc., Spark Investment Management LLC and Foundry Partners LLC. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie, Michael W Aguiar and Theodore J Jr Witek. View Insider Buying and Selling for Innoviva.
Who bought Innoviva stock? Who is buying Innoviva stock?
Innoviva's stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Renaissance Technologies LLC, Old Mutual Global Investors UK Ltd., LSV Asset Management, Guggenheim Capital LLC, Sawgrass Asset Management LLC, Arizona State Retirement System and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Innoviva.
How do I buy Innoviva stock?
Shares of Innoviva can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
One share of Innoviva stock can currently be purchased for approximately $16.35.
How big of a company is Innoviva?
Innoviva has a market capitalization of $1.77 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.12 on an earnings per share basis. Innoviva employs 14 workers across the globe.
How can I contact Innoviva?
Innoviva's mailing address is 2000 Sierra Point Pkwy Ste 500, BRISBANE, CA 94005-1830, United States. The biotechnology company can be reached via phone at +1-650-2389600 or via email at [email protected]
MarketBeat Community Rating for Innoviva (INVA)MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Innoviva (NASDAQ:INVA) Earnings History and Estimates Chart
Innoviva (NASDAQ INVA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/8/2018||Q4 2017||$0.49||$0.50||$67.41 million||$69.52 million||View||Listen|
|10/25/2017||Q3 2017||$0.34||$0.21||$57.18 million||$48.64 million||View||N/A|
|7/26/2017||Q2 2017||$0.28||$0.30||$50.53 million||$58.60 million||View||N/A|
|4/27/2017||Q1 2017||$0.27||$0.15||$47.66 million||$40.50 million||View||N/A|
|2/9/2017||Q4 2016||$0.19||$0.22||$40.72 million||$43.60 million||View||Listen|
|10/27/2016||Q316||$0.19||$0.16||$38.71 million||$33.30 million||View||Listen|
|7/28/2016||Q216||$0.12||$0.17||$31.13 million||$32.47 million||View||Listen|
|4/28/2016||Q116||$0.09||$0.04||$28.61 million||$24.17 million||View||Listen|
|2/3/2016||Q415||$0.01||$0.04||$20.17 million||$22.80 million||View||N/A|
|10/28/2015||Q315||($0.03)||($0.04)||$15.23 million||$13.56 million||View||Listen|
|7/29/2015||Q2||($0.06)||($0.07)||$10.90 million||$10.70 million||View||Listen|
|5/6/2015||Q115||($0.08)||($0.09)||$8.64 million||$6.90 million||View||Listen|
|2/18/2015||Q414||($0.14)||($0.14)||$5.42 million||$7.30 million||View||N/A|
|10/30/2014||Q314||($0.15)||($0.19)||$5.06 million||$1.00 million||View||N/A|
|8/6/2014||Q214||($0.53)||($0.18)||$4.39 million||$0.93 million||View||N/A|
|5/6/2014||Q114||($0.53)||($0.62)||$4.52 million||$0.17 million||View||N/A|
|2/6/2014||Q413||($0.38)||($0.46)||$6.03 million||$1.60 million||View||N/A|
|10/24/2013||Q313||$0.69||($0.44)||$3.08 million||$0.44 million||View||N/A|
|7/25/2013||Q2 2013||($0.46)||($0.37)||$1.43 million||$1.33 million||View||N/A|
|4/25/2013||Q1 2013||($0.38)||($0.39)||$2.71 million||$1.34 million||View||N/A|
|2/12/2013||Q4 2012||($0.36)||($0.33)||$3.88 million||$5.80 million||View||N/A|
Innoviva (NASDAQ:INVA) Earnings Estimates
Current Year EPS Consensus Estimate: $1.98 EPS
Next Year EPS Consensus Estimate: $2.28 EPS
Innoviva (NASDAQ:INVA) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Innoviva (NASDAQ INVA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.60%
Institutional Ownership Percentage: 72.39%
Innoviva (NASDAQ INVA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/4/2017||Michael W Aguiar||Insider||Sell||12,022||$13.13||$157,848.86||980,907|| |
|11/21/2017||Eric Desparbes||CFO||Sell||15,285||$13.28||$202,984.80||337,027|| |
|11/21/2017||George B Abercrombie||VP||Sell||5,215||$13.26||$69,150.90||263,866|| |
|8/21/2017||Eric Desparbes||CFO||Sell||1,825||$12.20||$22,265.00||344,993|| |
|5/22/2017||Eric Desparbes||CFO||Sell||1,825||$11.85||$21,626.25||352,588|| |
|5/22/2017||Theodore J Jr. Witek||VP||Sell||7,815||$12.01||$93,858.15||251,968|| |
|2/21/2017||Eric Desparbes||CFO||Sell||1,825||$12.07||$22,027.75||356,121|| |
|11/22/2016||Theodore L Witek Jr||VP||Sell||3,700||$10.84||$40,108.00||157,131|| |
|11/21/2016||Eric Desparbes||CFO||Sell||1,800||$10.89||$19,602.00|| |
|8/22/2016||Eric Desparbes||CFO||Sell||3,700||$11.77||$43,549.00||239,893|| |
|5/18/2016||James L Tyree||Director||Sell||813||$10.47||$8,512.11||50,697|| |
|5/11/2015||Plc Glaxosmithkline||Major Shareholder||Buy||85,579||$1,369,260.00||$117,179,901,540.00|| |
|8/13/2014||Junning Lee||VP||Sell||53,424||$22.50||$1,202,040.00|| |
|8/12/2014||Bradford J Shafer||SVP||Sell||28,156||$22.13||$623,092.28|| |
|8/11/2014||Bradford J Shafer||SVP||Sell||27,108||$22.12||$599,628.96|| |
|9/12/2013||Rick Winningham||CEO||Sell||22,353||$40.03||$894,790.59||690,106|| |
|7/30/2013||Mathai Mammen||SVP||Sell||7,000||$36.51||$255,570.00|| |
|6/7/2013||Bradford J Shafer||SVP||Sell||31,038||$35.04||$1,087,571.52|| |
|5/29/2013||David L Brinkley||Insider||Sell||3,808||$35.01||$133,318.08|| |
|5/13/2013||David L Brinkley||Insider||Sell||16,129||$40.33||$650,482.57|| |
|8/7/2012||Michael W Aguiar||CFO||Sell||60,000||$27.04||$1,622,400.00|| |
Innoviva (NASDAQ INVA) News Headlines
|How Do Analysts See Innoviva Inc (NASDAQ:INVA) Performing In The Years Ahead?|
finance.yahoo.com - February 19 at 9:03 AM
|Innoviva (INVA) Upgraded to "B" by TheStreet|
www.americanbankingnews.com - February 18 at 9:22 PM
|Innoviva Inc (INVA) Expected to Post Quarterly Sales of $73.83 Million|
www.americanbankingnews.com - February 17 at 7:02 AM
|$0.52 EPS Expected for Innoviva Inc (INVA) This Quarter|
www.americanbankingnews.com - February 15 at 5:10 AM
|GSK Submits IMPACT Data To EU To Support Trelegy Ellipta's Expanded Labelling|
www.nasdaq.com - February 14 at 9:08 AM
|Drug company Innoviva settles with activist hedge fund Sarissa -sources|
finance.yahoo.com - February 13 at 9:07 AM
|Innoviva (INVA) Rating Increased to Hold at Zacks Investment Research|
www.americanbankingnews.com - February 11 at 9:36 AM
|Contrasting Innoviva (INVA) and Eyegate Pharmaceuticals (EYEG)|
www.americanbankingnews.com - February 10 at 1:24 PM
|Innoviva (INVA) Rating Reiterated by Stifel Nicolaus|
www.americanbankingnews.com - February 9 at 1:04 PM
|Innoviva beats Street 4Q forecasts|
finance.yahoo.com - February 9 at 9:11 AM
|Innoviva (INVA) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS|
www.americanbankingnews.com - February 8 at 9:46 PM
|Innoviva Reports Record Fourth Quarter and Full Year 2017 Financial Results|
finance.yahoo.com - February 8 at 4:24 PM
|Innoviva Inc (INVA) Given Average Rating of "Hold" by Brokerages|
www.americanbankingnews.com - February 8 at 1:32 AM
|Innoviva (INVA) Downgraded to "Sell" at Zacks Investment Research|
www.americanbankingnews.com - February 3 at 11:12 AM
|Innoviva to Report Fourth Quarter Financial Results on February 8 at 5:00 p.m. EDT|
finance.yahoo.com - February 2 at 4:37 PM
|Innoviva Inc (INVA) Expected to Post Quarterly Sales of $65.18 Million|
www.americanbankingnews.com - January 31 at 6:58 AM
|Innoviva (INVA) to Release Earnings on Wednesday|
www.americanbankingnews.com - January 31 at 2:28 AM
|Innoviva Inc (INVA) Expected to Announce Quarterly Sales of $66.75 Million|
www.americanbankingnews.com - January 14 at 9:58 AM
|Innoviva Inc (INVA) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - January 14 at 1:32 AM
| Brokerages Anticipate Innoviva Inc (INVA) Will Announce Earnings of $0.45 Per Share|
www.americanbankingnews.com - January 12 at 9:30 AM
|Head-To-Head Analysis: Tetraphase Pharmaceuticals (TTPH) vs. Innoviva (INVA)|
www.americanbankingnews.com - January 10 at 8:02 AM
|Validea Joel Greenblatt Strategy Daily Upgrade Report - 1/5/2018 ... - Nasdaq|
www.nasdaq.com - January 5 at 8:01 AM
|Innoviva Sees RS Rating Rise To 74|
finance.yahoo.com - December 27 at 11:40 AM
|Zacks: Brokerages Anticipate Innoviva Inc (INVA) Will Announce Earnings of $0.45 Per Share|
www.americanbankingnews.com - December 26 at 7:21 PM
|Innoviva Earns Relative Strength Rating Upgrade|
finance.yahoo.com - December 22 at 11:26 AM
|Innoviva (INVA) Upgraded at BidaskClub|
www.americanbankingnews.com - December 21 at 11:28 PM
|ETFs with exposure to Innoviva, Inc. : December 21, 2017|
finance.yahoo.com - December 21 at 3:24 PM
|Innoviva Inc (INVA) Given Average Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - December 20 at 1:28 AM
|Amicus Therapeutics (FOLD) and Innoviva (INVA) Financial Contrast|
www.americanbankingnews.com - December 14 at 1:28 PM
|Innoviva, Inc. breached its 50 day moving average in a Bullish Manner : INVA-US : December 12, 2017|
finance.yahoo.com - December 12 at 7:49 AM
|$66.75 Million in Sales Expected for Innoviva, Inc. (INVA) This Quarter|
www.americanbankingnews.com - December 11 at 1:00 PM
|Analyzing Innoviva (INVA) and Johnson & Johnson (JNJ)|
www.americanbankingnews.com - December 9 at 9:36 AM
|Innoviva, Inc. (INVA) Expected to Post Earnings of $0.45 Per Share|
www.americanbankingnews.com - December 9 at 5:30 AM
|Insider Selling: Innoviva, Inc. (INVA) Insider Sells 12,022 Shares of Stock|
www.americanbankingnews.com - December 5 at 7:14 PM
|ETFs with exposure to Innoviva, Inc. : December 1, 2017|
finance.yahoo.com - December 1 at 3:25 PM
|Innoviva, Inc. :INVA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017|
finance.yahoo.com - November 30 at 11:58 AM
|Comparing Innoviva (INVA) and Its Rivals|
www.americanbankingnews.com - November 27 at 5:22 PM
|Analyzing Innoviva (INVA) & Its Competitors|
www.americanbankingnews.com - November 25 at 11:04 PM
|Innoviva, Inc. (INVA) Receives Average Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - November 25 at 1:48 AM
|Innoviva, Inc. (INVA) Expected to Post Quarterly Sales of $63.27 Million|
www.americanbankingnews.com - November 23 at 12:52 PM
|Innoviva, Inc. breached its 50 day moving average in a Bullish Manner : INVA-US : November 22, 2017|
finance.yahoo.com - November 23 at 2:26 AM
|George B. Abercrombie Sells 5,215 Shares of Innoviva, Inc. (INVA) Stock|
www.americanbankingnews.com - November 22 at 8:44 PM
|Innoviva, Inc. (INVA) CFO Sells $202,984.80 in Stock|
www.americanbankingnews.com - November 22 at 8:23 PM
|Innoviva, Inc. (INVA) Earns Hold Rating from Analysts at Deutsche Bank AG|
www.americanbankingnews.com - November 20 at 8:52 PM
|Innoviva Reaches Analyst Target Price|
www.thestreet.com - November 20 at 4:43 PM
|Corporate News Blog - GlaxoSmithKline and Innoviva’s Trelegy Ellipta Gets Marketing Authorization for the Treatment of COPD in Europe|
finance.yahoo.com - November 20 at 4:43 PM
|Comparing Innoviva (INVA) & Its Rivals|
www.americanbankingnews.com - November 19 at 9:28 AM
|Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU|
www.zacks.com - November 18 at 2:23 AM
|Innoviva (INVA) and Its Peers Head to Head Survey|
www.americanbankingnews.com - November 16 at 7:10 PM
|Largest Shareholders of GlaxcoSmithKline|
finance.yahoo.com - November 9 at 6:53 AM
Innoviva (NASDAQ:INVA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Innoviva (NASDAQ:INVA) Income Statement, Balance Sheet and Cash Flow Statement
Innoviva (NASDAQ INVA) Stock Chart for Wednesday, February, 21, 2018